Browse studies

Find your next paid study

1 recruiting study matching your filters

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Background: CAR (Chimeric Antigen Receptor) T cell therapy is a type of cancer treatment in which a person s T cells (a type of immune cell) are changed in a …

Hairy Cell LeukemiaHairy Cell Leukemia Variant

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04815356